Low back pain affected 619 million people in 2020 and is the single leading cause of disability worldwide. Cases are projected to reach 843 million by 2050, with the sharpest growth in Africa and Asia.
157 of these 221 lines are oral and 34 injectable, with 29 diclofenac and 29 aceclofenac presentations across both.
Range depth
9 etoricoxib and 29 aceclofenac presentations.
15 thiocolchicoside presentations, oral and injectable.
13 trypsin combination presentations.
34 injectable lines in the category.
We establish what is already registered in your market, who supplies it today, and where demand is going unmet.
We set your current range against the portfolio and separate genuine gaps from lines you already stock.
You get the molecules in filing order, which of them need a dossier built for your authority, and which fall outside the range.
We compile the dossier in CTD format for your authority and supply the COPP and plant-level WHO-GMP and PIC/S certificates behind it.
Controlled-substance lines are supplied subject to narcotics licensing in both jurisdictions.
We analyse your market and set your existing range against the portfolio, then return the molecules worth filing in priority order with the documentation route for each.